IL-23R Arg381Gln polymorphism in Chilean patients with inflammatory bowel disease

Mauricio Venegas, Caroll J. Beltrán, Luis Álvarez, Ariel Castro, Tamara Torres, Andrea D. Leal, Francisca M. Lahsen, Marcela A. Hermoso, Rodrigo Quera*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Crohn's disease (CD) and ulcerative colitis (UC) are multifactorial diseases with a genetic background. Recent results have shown that a non-synonymous, single nucleotide polymorphism (rs11209026, c.1142G>A, p.Arg381Gln) located in the IL-23R gene is associated with inflammatory bowel disease (IBD). The prevalence of IBD is rapidly rising in Chile and there is no information about the frequency of this polymorphism in the Chilean population. Aim. To assess the distribution of DNA variants in the IL-23R gene in Chilean patients with IBD. Methods. We studied 100 IBD patients (38 CD and 62 UC) and 59 healthy controls. IL-23R Arg381Gln (G1142A) was genotyped by the polymerase chain reaction and restriction fragment length polymorphism assay. Clinical and demographic features were characterized. Results. The IL-23R genetic variant did not have an association with IBD in Chilean patients. This polymorphism was present in 5.2% of the control group and 5% of IBD patients (7.9% for CD and 3.2% for UC) (p > 0.05). Conclusions. These results suggest that the IL-23R Arg381Gln seems not to be involved in the genetic predisposition to IBD in a Chilean population, and confirms that there are ethnic differences in the genetic background of IBD. Replication studies by independent groups are necessary to elucidate the contribution of susceptibility genes to IBD in different ethnic populations.

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalEuropean Cytokine Network
Issue number4
StatePublished - Dec 2008
Externally publishedYes


  • Chilean
  • IL-23R
  • Inflammatory bowel disease


Dive into the research topics of 'IL-23R Arg381Gln polymorphism in Chilean patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this